[go: up one dir, main page]

RU2013128920A - METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION - Google Patents

METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION Download PDF

Info

Publication number
RU2013128920A
RU2013128920A RU2013128920/15A RU2013128920A RU2013128920A RU 2013128920 A RU2013128920 A RU 2013128920A RU 2013128920/15 A RU2013128920/15 A RU 2013128920/15A RU 2013128920 A RU2013128920 A RU 2013128920A RU 2013128920 A RU2013128920 A RU 2013128920A
Authority
RU
Russia
Prior art keywords
kcal
source
human
present
level
Prior art date
Application number
RU2013128920/15A
Other languages
Russian (ru)
Inventor
Аня УИТТКЕ
Сесилия МУНОЗ
Даттатрея БАНАВАРА
Роберт Дж. МАКМАХОН
Original Assignee
ЭмДжейЭн Ю.Эс. Холдингс ЛЛК
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/980,813 external-priority patent/US8648036B2/en
Priority claimed from US12/980,808 external-priority patent/US20120171163A1/en
Application filed by ЭмДжейЭн Ю.Эс. Холдингс ЛЛК filed Critical ЭмДжейЭн Ю.Эс. Холдингс ЛЛК
Publication of RU2013128920A publication Critical patent/RU2013128920A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pediatric Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1. Способ ингибирования по меньшей мере одного механизма инвазии бактериального патогена, включающий введение человеку питательной композиции, содержащей:a) липид или жир;b) источник белка;c) примерно от 0,1 примерно до 1 г/100 ккал композиции пребиотика, где композиция пребиотика содержит по меньшей мере 20% олигосахарида;d) по меньшей мере примерно 10 мг/100 ккал лактоферрина, полученного из источника, не являющегося человеком.2. Способ по п. 1, где питательная композиция дополнительно содержит примерно от 5 примерно до 100 мг/100 ккал источника полиненасыщенных жирных кислот с длинной цепью, который содержит докозагексаеновую кислоту.3. Способ по п. 2, где источник полиненасыщенных жирных кислот с длинной цепью дополнительно содержит арахидоновую кислоту.4. Способ по п. 1, где липид или жир присутствуют на уровне примерно до 7 г/100 ккал.5. Способ по п. 1, где источник белка присутствует на уровне примерно до 5 г/100 ккал.6. Способ по п. 1, где олигосахарид содержит галактоолигосахарид.7. Способ по п. 6, где олигосахарид дополнительно содержит полидекстрозу.8. Способ по п. 1, где лактоферрин присутствует на уровне примерно от 70 мг примерно до 220 мг/100 ккал.9. Способ ингибирования адгезии по меньшей мере одного патогена в желудочно-кишечном тракте человека, включающий введение человеку питательной композиции, содержащей:a) источник жира или липида;b) источник белка;c) лактоферрин, полученный из источника, не являющегося человеком; иd) пребиотическую композицию, содержащую соединение, выбранное из группы, состоящей из галактоолигосахарида, полидекстрозы и их сочетания.10. Способ по п. 9, где по меньшей мере один патоген содержит Enterobacter sazakaii или Е. coli1. A method of inhibiting at least one bacterial pathogen invasion mechanism, comprising administering to a human a nutritional composition comprising: a) a lipid or fat; b) a protein source; c) from about 0.1 to about 1 g / 100 kcal of the prebiotic composition, wherein the prebiotic composition contains at least 20% oligosaccharide; d) at least about 10 mg / 100 kcal of lactoferrin obtained from a non-human source. The method of claim 1, wherein the nutritional composition further comprises from about 5 to about 100 mg / 100 kcal of a long chain polyunsaturated fatty acid source that contains docosahexaenoic acid. The method of claim 2, wherein the source of the long chain polyunsaturated fatty acids further comprises arachidonic acid. The method of claim 1, wherein the lipid or fat is present at a level of about 7 g / 100 kcal. The method of claim 1, wherein the protein source is present at about 5 g / 100 kcal. 6. The method of claim 1, wherein the oligosaccharide contains galactooligosaccharide. The method of claim 6, wherein the oligosaccharide further comprises polydextrose. The method of claim 1, wherein the lactoferrin is present at a level of from about 70 mg to about 220 mg / 100 kcal. A method of inhibiting the adhesion of at least one pathogen in the human gastrointestinal tract, comprising administering to the human a nutritional composition comprising: a) a source of fat or lipid; b) a source of protein; c) lactoferrin obtained from a non-human source; and d) a prebiotic composition containing a compound selected from the group consisting of galactooligosaccharide, polydextrose, and combinations thereof. 10. The method of claim 9, wherein the at least one pathogen comprises Enterobacter sazakaii or E. coli

Claims (15)

1. Способ ингибирования по меньшей мере одного механизма инвазии бактериального патогена, включающий введение человеку питательной композиции, содержащей:1. A method of inhibiting at least one bacterial pathogen invasion mechanism, comprising administering to a human a nutritional composition comprising: a) липид или жир;a) lipid or fat; b) источник белка;b) a protein source; c) примерно от 0,1 примерно до 1 г/100 ккал композиции пребиотика, где композиция пребиотика содержит по меньшей мере 20% олигосахарида;c) from about 0.1 to about 1 g / 100 kcal of the prebiotic composition, wherein the prebiotic composition contains at least 20% oligosaccharide; d) по меньшей мере примерно 10 мг/100 ккал лактоферрина, полученного из источника, не являющегося человеком.d) at least about 10 mg / 100 kcal of lactoferrin obtained from a non-human source. 2. Способ по п. 1, где питательная композиция дополнительно содержит примерно от 5 примерно до 100 мг/100 ккал источника полиненасыщенных жирных кислот с длинной цепью, который содержит докозагексаеновую кислоту.2. The method of claim 1, wherein the nutritional composition further comprises from about 5 to about 100 mg / 100 kcal of a long chain polyunsaturated fatty acid source that contains docosahexaenoic acid. 3. Способ по п. 2, где источник полиненасыщенных жирных кислот с длинной цепью дополнительно содержит арахидоновую кислоту.3. The method of claim 2, wherein the source of the long chain polyunsaturated fatty acids further comprises arachidonic acid. 4. Способ по п. 1, где липид или жир присутствуют на уровне примерно до 7 г/100 ккал.4. The method of claim 1, wherein the lipid or fat is present at a level of about 7 g / 100 kcal. 5. Способ по п. 1, где источник белка присутствует на уровне примерно до 5 г/100 ккал.5. The method of claim 1, wherein the protein source is present at a level of about 5 g / 100 kcal. 6. Способ по п. 1, где олигосахарид содержит галактоолигосахарид.6. The method according to claim 1, where the oligosaccharide contains galactooligosaccharide. 7. Способ по п. 6, где олигосахарид дополнительно содержит полидекстрозу.7. The method of claim 6, wherein the oligosaccharide further comprises polydextrose. 8. Способ по п. 1, где лактоферрин присутствует на уровне примерно от 70 мг примерно до 220 мг/100 ккал.8. The method of claim 1, wherein the lactoferrin is present at a level of from about 70 mg to about 220 mg / 100 kcal. 9. Способ ингибирования адгезии по меньшей мере одного патогена в желудочно-кишечном тракте человека, включающий введение человеку питательной композиции, содержащей:9. A method of inhibiting the adhesion of at least one pathogen in the human gastrointestinal tract, comprising administering to the human a nutritional composition comprising: a) источник жира или липида;a) a source of fat or lipid; b) источник белка;b) a protein source; c) лактоферрин, полученный из источника, не являющегося человеком; иc) lactoferrin obtained from a non-human source; and d) пребиотическую композицию, содержащую соединение, выбранное из группы, состоящей из галактоолигосахарида, полидекстрозы и их сочетания.d) a prebiotic composition containing a compound selected from the group consisting of galactooligosaccharide, polydextrose, and combinations thereof. 10. Способ по п. 9, где по меньшей мере один патоген содержит Enterobacter sazakaii или Е. coli.10. The method of claim 9, wherein the at least one pathogen comprises Enterobacter sazakaii or E. coli. 11. Способ по п. 9, где питательная композиция дополнительно содержит примерно от 5 примерно до 100 мг/100 ккал источника полиненасыщенных жирных кислот с длинной цепью, который содержит докозагесаноевую кислоту.11. The method according to claim 9, where the nutritional composition further comprises from about 5 to about 100 mg / 100 kcal of a source of long chain polyunsaturated fatty acids, which contains docosahexanoic acid. 12. Способ по п. 11, где источник полиненасыщенных жирных кислот с длинной цепью дополнительно содержит арахидоновую кислоту.12. The method of claim 11, wherein the source of the long chain polyunsaturated fatty acids further comprises arachidonic acid. 13. Способ по п. 9, где источник жира или липида присутствует на уровне примерно от 3 г/100 ккал примерно до 7 г/100 ккал.13. The method of claim 9, wherein the source of fat or lipid is present at a level of from about 3 g / 100 kcal to about 7 g / 100 kcal. 14. Способ по п. 9, где источник белка присутствует на уровне примерно от 1 г/100 ккал примерно до 5 г/100 ккал.14. The method of claim 9, wherein the protein source is present at a level of from about 1 g / 100 kcal to about 5 g / 100 kcal. 15. Способ по п. 9, где лактоферрин присутствует на уровне примерно от 70 мг/100 ккал примерно до 220 мг/100 ккал. 15. The method of claim 9, wherein the lactoferrin is present at a level of from about 70 mg / 100 kcal to about 220 mg / 100 kcal.
RU2013128920/15A 2010-12-29 2011-12-15 METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION RU2013128920A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/980,813 US8648036B2 (en) 2010-12-29 2010-12-29 Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract
US12/980,813 2010-12-29
US12/980,808 2010-12-29
US12/980,808 US20120171163A1 (en) 2010-12-29 2010-12-29 Method for inhibiting a bacterial invasive mechanism using a nutritional composition
PCT/US2011/065231 WO2012091946A2 (en) 2010-12-29 2011-12-15 Method for inhibiting pathogens using a nutritional composition

Publications (1)

Publication Number Publication Date
RU2013128920A true RU2013128920A (en) 2015-02-10

Family

ID=45496273

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013128920/15A RU2013128920A (en) 2010-12-29 2011-12-15 METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION

Country Status (13)

Country Link
EP (1) EP2658388A2 (en)
CN (1) CN103327828B (en)
BR (1) BR112013011642B1 (en)
CA (1) CA2822892C (en)
EC (1) ECSP13012798A (en)
MX (1) MX2013006094A (en)
MY (1) MY174494A (en)
PE (1) PE20141192A1 (en)
PH (1) PH12013500916A1 (en)
RU (1) RU2013128920A (en)
SG (2) SG190781A1 (en)
TW (1) TWI626893B (en)
WO (1) WO2012091946A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968722B2 (en) 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
MY172595A (en) * 2012-12-18 2019-12-04 Mjn Us Holdings Llc Milk-based nutritional compositions containing lactoferrin and uses thereof
US20140271978A1 (en) * 2013-03-15 2014-09-18 Mead Johnson Nutrition Company Low-buffer nutritional compositions and uses thereof
US9609888B2 (en) * 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
WO2019049157A1 (en) * 2017-09-10 2019-03-14 Technion Research & Development Foundation Limited Composition and method for a prebiotic delivery system targeted to probiotic bacteria
GB2618609A (en) * 2022-05-13 2023-11-15 Lintbells Ltd Methods and processes for manufacture of a topically adherent selective bactericide
EP4586831A1 (en) 2022-09-14 2025-07-23 N.V. Nutricia Nutritional composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61701B1 (en) 1986-07-17 1994-11-30 Morinaga Milk Industry Co Ltd Process for producing bovine lactoferrin in high purity
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
EP1961312A3 (en) 1991-01-24 2010-03-31 Martek Biosciences Corporation Microbial oil mixture and uses thereof
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
DE69524386D1 (en) 1994-02-16 2002-01-17 Pharming Intellectual Pty Bv ISOLATION OF LACTOFERRIN FROM MILK
AU2003218623B2 (en) 2002-03-07 2008-01-17 Upfront Chromatography A/S A process of isolating lactoferrin
CN101247823A (en) * 2005-05-05 2008-08-20 布里斯托尔-迈尔斯斯奎布公司 Application of bovine lactoferrin in preparation of medicine for inhibiting bacterial growth
US20070191264A1 (en) * 2005-05-05 2007-08-16 Bristol-Myers Squibb Company, A Delaware Corporation Methods for inhibiting the growth of bacteria
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
WO2008047391A1 (en) * 2006-10-17 2008-04-24 S.I.F.Fr.A. Farmaceutici Srl Nutriceutic composition comprising lactoferrin and proteasic probiotics
KR20100103468A (en) * 2007-11-26 2010-09-27 네스텍 소시에테아노님 Age-tailored nutrition system for infants
ITRM20080163A1 (en) * 2008-03-26 2009-09-27 Maurizio Acri USE OF LATTOFERRINA FOR THE PREVENTION OF NEONATAL SEPSIS IN PREMATURED NEWBORNS
US8425955B2 (en) * 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
PH12012500737A1 (en) * 2009-10-29 2012-11-26 Nestec Sa Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof

Also Published As

Publication number Publication date
CN103327828B (en) 2016-05-11
CN103327828A (en) 2013-09-25
MY174494A (en) 2020-04-23
SG190781A1 (en) 2013-07-31
EP2658388A2 (en) 2013-11-06
BR112013011642A2 (en) 2016-07-12
HK1189456A1 (en) 2014-06-13
MX2013006094A (en) 2013-07-03
WO2012091946A2 (en) 2012-07-05
PH12013500916A1 (en) 2024-06-03
TW201238503A (en) 2012-10-01
BR112013011642B1 (en) 2020-04-07
TWI626893B (en) 2018-06-21
WO2012091946A3 (en) 2012-09-07
ECSP13012798A (en) 2013-09-30
SG10201508194RA (en) 2015-11-27
CA2822892A1 (en) 2012-07-05
PE20141192A1 (en) 2014-10-01
CA2822892C (en) 2020-04-28

Similar Documents

Publication Publication Date Title
RU2013128920A (en) METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION
Awuchi et al. Bioactive compounds and therapeutics from fish: revisiting their suitability in functional foods to enhance human wellbeing
RU2011120780A (en) NUTRITIONAL COMPOSITION PROMOTING HEALTHY DEVELOPMENT AND GROWTH
ES2554230T3 (en) Liquid enteral nutritional composition with a low content of monovalent metal ions
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
MX2014005433A (en) Methods and compositions for modulating gastrointestinal bacteria to promote health.
RU2010129984A (en) COMPOSITIONS OF NUTRIENT POWDER AND BABY NUTRITION MIXTURE (OPTIONS)
RU2010129985A (en) COMPOSITIONS OF NUTRIENT POWDER AND BABY NUTRITION MIXTURE (OPTIONS)
PH12016500026A1 (en) Nutritional compositions containing synergistic combination and uses thereof
RU2013148072A (en) VITAMINIZED NUTRITION COMPOSITIONS BASED ON MILK
MA35195B1 (en) Algal lipid compositions, methods for their preparation and their uses
RU2010119238A (en) COMPOSITION FOR IMPROVING THE FUNCTION OF THE GASTROINTESTINAL TRACT
RU2012139658A (en) COMPOSITIONS AND METHODS FOR DELIVERY OF NUTRIENTS
RU2015122497A (en) LACTOFERRINE-CONTAINING NUTRITIONAL COMPOSITIONS ON THE BASIS OF MILK AND THEIR APPLICATION
Sanjulián et al. The Role of Dairy in Human Nutrition: Myths and Realities
RU2015139356A (en) LOW BOFFER NUTRITION COMPOSITIONS AND THEIR APPLICATION
MX338223B (en) Fat emulsion for artificially feeding seriously ill intensive care patients.
RU2015139557A (en) RISK REDUCTION OF AUTOIMMUNE DISEASE
RU2013134133A (en) APPLICATION OF LACTOFERRINE-CONTAINING NUTRITIONAL COMPOSITIONS IN MAINTAINING RESISTANCE TO DISEASES AND CONDITIONS
JP2014504261A5 (en)
RU2008117138A (en) METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
Undeland et al. Seafood and health: what is the full story?
MX2011007222A (en) Nutritional composition for infants.
RU2010151892A (en) WAYS TO REDUCE LIPID ABSORPTION IN ANIMALS
RU2015133023A (en) ACTIVATION OF ADIPONECTIN USING CASEIN HYDROLYSATE

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20170125